targeted cancer diagnostic and therapeutic agents: delivery by carriers or conjugation

Authors

mohsen mohammadgholi phd student of radiopharmacy, faculty of pharmacy, mazandaran university of medical sciences, sari, iran

farzaneh rezazadeh phd student of radiopharmacy, faculty of pharmacy, mazandaran university of medical sciences, sari, iran

nourollah sadeghzadeh assistant professor of radiopharmacy science, faculty of pharmacy, mazandaran university of medical sciences, sari, mazandaran, iran

abstract

receptors and proteins are overexpressed in many human cancer cell membranes rather than normal tissues and are considered as the main molecular targets. specific tumor- targeting molecules which have high affinity for these receptors can be valuable tools as carrier molecules for targeted cancer therapy and imaging. pharmacokinetics and bioavailability of diagnostic and therapeutic agents are very important. poor selectivity of cancer therapeutic agents causes toxicity on normal cells that limits maximum effective dose. the attachment of these agents to macromolecules or their installation on carriers is currently under investigation. this article presents recent developments in the field of targeting agents and introduces different carriers and their applications in the diagnosis and treatment of cancer.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Targeted Cancer Diagnostic and Therapeutic Agents: Delivery by Carriers or Conjugation

Receptors and proteins are overexpressed in many human cancer cell membranes rather than normal tissues and are considered as the main molecular targets. Specific tumor- targeting molecules which have high affinity for these receptors can be valuable tools as carrier molecules for targeted cancer therapy and imaging. Pharmacokinetics and bioavailability of diagnostic and therapeutic agents are ...

full text

Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.

We report that a lipoprotein-based nanoplatform generated by conjugating tumor-homing molecules to the protein components of naturally occurring lipoproteins reroutes them from their normal lipoprotein receptors to other selected cancer-associated receptors. Multiple copies of these targeting moieties may be attached to the same nanoparticle, or a variety of different targeting moieties can be ...

full text

Aptamer-based Targeted Delivery of miRNA let-7d to Gastric Cancer Cells as a Novel Anti-Tumor Therapeutic Agent

miRNAs as one of the potential therapeutic agents have been recently considered for cancer treatment. AS1411 (aptNCL) is a DNA aptamer specifically binding to nucleolin protein on the cancer cell surface with antiproliferative effect. The aim of the study was to develop a conjugate consisted of aptNCL (as targeted delivery of therapeutic agent) and miRNA let-7d (as a tumor suppressor) using two...

full text

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

PURPOSE Corticosteroids are widely used for the treatment of B-cell malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia; however, this class of drug is associated with undesirable off-target effects. Herein, we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74(+) B-...

full text

Cancer Therapy: Preclinical Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74þ B-cell Malignancies

Purpose: Corticosteroids are widely used for the treatment of B-cell malignancies, including non– Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia; however, this class of drug is associated with undesirable off-target effects. Herein, we developed novel milatuzumabconjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74þ B-c...

full text

Aptamer-based Targeted Delivery of miRNA let-7d to Gastric Cancer Cells as a Novel Anti-Tumor Therapeutic Agent

miRNAs as one of the potential therapeutic agents have been recently considered for cancer treatment. AS1411 (aptNCL) is a DNA aptamer specifically binding to nucleolin protein on the cancer cell surface with antiproliferative effect. The aim of the study was to develop a conjugate consisted of aptNCL (as targeted delivery of therapeutic agent) and miRNA let-7d (as a tumor suppressor) using two...

full text

My Resources

Save resource for easier access later


Journal title:
research in molecular medicine

جلد ۴، شماره ۳، صفحات ۳-۹

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023